Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook
Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript
Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
